BridgeBio Pharma Target Price

Where could BBIO trade next? Consensus target price: $110.

Get informed when a big investor buys or sells

+ Follow

Share Price

$83.84

Average Target Price

$109.25

30.3% upside

8 analysts in the last 4 months

High: $130 | Low: $96

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-07-13	H.C. Wainwright	$120	43.1% upside
2026-06-16	Mizuho SecuritiesSalim Syed	$96	14.5% upside
2026-06-03	Canaccord Genuity	$104	24% upside
2026-05-28	Morgan Stanley	$98	16.9% upside
2026-05-11	H.C. Wainwright	$110	31.2% upside
2026-05-08	Bernstein	$114	36% upside
2026-05-08	Evercore ISI	$130	55.1% upside
2026-04-29	Truist FinancialDanielle Brill	$102	21.7% upside
2026-04-08	RBC CapitalLuca Issi	$100	19.3% upside
2026-03-12	Leerink PartnersMani Foroohar	$98	16.9% upside
2026-02-25	Truist FinancialDanielle Brill	$95	13.3% upside
2026-02-17	H.C. WainwrightRaghuram Selvaraju	$100	19.3% upside
2026-02-13	Tudor PickeringWilliam Pickering	$100	19.3% upside
2026-02-13	OppenheimerTrevor Allred	$83	1% downside
2026-02-12	JefferiesAndrew Tsai	$100	19.3% upside
2026-02-12	Raymond JamesMartin Auster	$89	6.2% upside
2026-01-27	Barclays	$157	87.3% upside
2026-01-20	Wells FargoTiago Fauth	$88	5% upside
2026-01-08	Truist Financial	$86	2.6% upside
2026-01-06	Morgan Stanley	$96	14.5% upside
2025-12-15	Leerink Partners	$86	2.6% upside
2025-12-11	Bernstein	$94	12.1% upside
2025-10-30	Truist Financial	$80	4.6% downside
2025-10-30	Oppenheimer	$81	3.4% downside
2025-10-30	Piper Sandler	$98	16.9% upside
2025-10-30	Goldman SachsPaul Choi	$100	19.3% upside
2025-10-29	H.C. Wainwright	$90	7.3% upside
2025-10-28	H.C. Wainwright	$80	4.6% downside
2025-10-27	Raymond James	$69	17.7% downside
2025-10-27	Leerink PartnersMani Foroohar	$68	18.9% downside
2025-08-29	H.C. WainwrightRaghuram Selvaraju	$70	16.5% downside
2025-04-30	UBSEliana Merle	$72	14.1% downside
2024-10-24	CitigroupDavid Lebowitz	$45	46.3% downside
2024-10-17	Leerink PartnersMani Foroohar	$46	45.1% downside
2024-09-11	Piper SandlerBiren Amin	$46	45.1% downside
2024-09-03	Mizuho SecuritiesSalim Syed	$53	36.8% downside
2024-06-24	Raymond JamesDanielle Brill	$46	45.1% downside
2024-06-05	BMO CapitalKostas Biliouris	$37	55.9% downside
2024-06-05	Wells FargoTiago Fauth	$58	30.8% downside
2024-05-30	Goldman SachsPaul Choi	$50	40.4% downside
2024-05-28	UBSEliana Merle	$47	43.9% downside
2024-05-20	H.C. WainwrightRaghuram Selvaraju	$43	48.7% downside
2024-05-13	Evercore ISICory Kasimov	$50	40.4% downside
2022-11-18	J.P. Morgan	$19	77.3% downside
2022-03-17	Raymond JamesDane Leone	$17	79.7% downside

BridgeBio Pharma (BBIO) FAQ

BridgeBio Pharma posts a target price of $110. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $110 for BBIO means covering analysts, on average, see the stock 30.3% upside of $83.84 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for BBIO's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; BridgeBio Pharma's other metric pages and overview cover the third.

Judging BridgeBio Pharma against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $110 here, then scan peer and history charts to see if the gap is persistent.